IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

CHUCK SHAMMAS, Individually and On Behalf of All Others Similarly Situated,)
Plaintiff,))) Case No.
v.)) JURY TRIAL DEMANDED
ALCOBRA LTD., YARON DANIELY, HOWARD B. ROSEN, JOAO SIFFERT,)) CLASS ACTION
DANIEL E. GEFFKEN, ORLI TORI,)
AHARON SCHWARTZ, ARIEH BEN YOSEF, OFER SEGEV, AMIR EFRATI,)
YUVAL YANAI, ARCTURUS THERAPEUTICS, INC., and ALEPH))
MERGERSUB, INC.,)
Defendants.)

COMPLAINT FOR VIOLATION OF THE SECURITIES EXCHANGE ACT OF 1934

Plaintiff, by his undersigned attorneys, for this complaint against defendants, alleges upon personal knowledge with respect to himself, and upon information and belief based upon, *inter alia*, the investigation of counsel as to all other allegations herein, as follows:

NATURE OF THE ACTION

- 1. This action stems from a proposed transaction announced on September 27, 2017 (the "Proposed Transaction"), pursuant to which Alcobra Ltd. ("Alcobra" or the "Company") will merge with Arcturus Therapeutics, Inc. ("Arcturus") in an all-stock transaction.
- 2. On September 27, 2017, Alcobra's Board of Directors (the "Board" or "Individual Defendants") caused the Company to enter into an agreement and plan of merger (the "Merger Agreement") with Arcturus and Aleph Mergersub Inc. ("Merger Sub").
- 3. Pursuant to the terms of the Merger Agreement, the holders of Arcturus outstanding capital stock immediately prior to the merger will receive ordinary shares of

Alcobra. As a result of the Proposed Transaction, Alcobra shareholders are expected to own approximately 40% and Arcturus shareholders are expected to own approximately 60% of the combined company.

- 4. The Proposed Transaction is expected to close during the fourth quarter of 2017, subject to, among other things, the approval by Alcobra's stockholders.
- 5. On September 28, 2017, Alcobra filed two Form 6-Ks with the United States Securities and Exchange Commission ("SEC") in connection with the Proposed Transaction.
- 6. The first Form 6-K attached a copy of the Merger Agreement as well as a press release announcing the Proposed Transaction (the "Press Release"). The Press Release stated, in relevant part:

A proxy statement and a proxy card will be filed with the SEC and will be mailed to Alcobra's shareholders seeking any required shareholder approvals in connection with the proposed transactions. Before making any voting or investment decision, investors and shareholders are urged to read the proxy statement (including any amendments or supplements thereto) and any other relevant documents that Alcobra may file with the SEC when they become available because they will contain important information about the proposed transactions.

- 7. The second Form 6-K attached a Notice of an Extraordinary General Meeting of Shareholders to be held on November 2, 2017 in connection with the Proposed Transaction (the "Stockholder Vote").
- 8. Neither Form 6-K filed on September 28, 2017 attached a proxy statement or proxy card.
- 9. To date, Alcobra has not filed a proxy statement or proxy card with the SEC in connection with the Proposed Transaction, and plaintiff has not received a proxy statement or proxy card by mail.
 - 10. Accordingly, plaintiff seeks to enjoin the November 2, 2017 Stockholder Vote on

the Proposed Transaction, as stockholders cannot make an informed decision with respect to the merger without a proxy statement.

JURISDICTION AND VENUE

- 11. This Court has jurisdiction over the claims asserted herein pursuant to Section 27 of the 1934 Act because the claims asserted herein arise under Sections 14(a) and 20(a) of the 1934 Act and Rule 14a-9.
- 12. This Court has jurisdiction over defendants because each defendant is either a corporation that conducts business in and maintains operations within this District, or is an individual with sufficient minimum contacts with this District so as to make the exercise of jurisdiction by this Court permissible under traditional notions of fair play and substantial justice.
- 13. Venue is proper under 28 U.S.C. § 1391(b) because a substantial portion of the transactions and wrongs complained of herein occurred in this District.

PARTIES

- 14. Plaintiff is, and has been continuously throughout all times relevant hereto, the owner of Alcobra common stock.
- 15. Defendant Alcobra is an Israeli company with its United States offices located at 101 West Elm Street, Suite 350, Conshohocken, PA 19428. Alcobra's common stock is traded on the NasdaqGM under the ticker symbol "ADHD."
- 16. Defendant Yaron Daniely ("Daniely") is Chairman of the Board of Alcobra, and previously served as President and Chief Executive Officer ("CEO") of Alcobra from 2010 through May 2017.
- 17. Defendant Howard B. Rosen ("Rosen") has served as a director of Alcobra since May 2013.

- 18. Defendant Joao Siffert ("Siffert") has served as a director of Alcobra since July 2015.
- 19. Defendant Daniel E. Geffken ("Geffken") has served as a director of Alcobra since May 2013.
- 20. Defendant Orli Tori ("Tori") has served as a director of Alcobra since August 2016.
- 21. Defendant Aharon Schwartz ("Schwartz") has served as a director of Alcobra since January 2013, and previously served as Chairman of the Board of Alcobra from January 2013 through February 2014.
- 22. Defendant Arieh Ben Yosef ("Yosef") has served as a director of Alcobra since May 2014.
- 23. Defendant Ofer Segev ("Segev") has served as a director of Alcobra since August 2016.
- 24. Defendant Amir Efrati ("Efrati") has served as a director of Alcobra since June 2017.
- 25. Defendant Yuval Yanai ("Yanai") has served as a director of Alcobra since June 2017.
- 26. The defendants identified in paragraphs 16 through 25 are collectively referred to herein as the "Individual Defendants."
- 27. Defendant Arcturus is a Delaware corporation and a party to the Merger Agreement.
- 28. Defendant Merger Sub is a Delaware corporation and a party to the Merger Agreement.

CLASS ACTION ALLEGATIONS

- 29. Plaintiff brings this action as a class action on behalf of himself and the other public stockholders of Alcobra (the "Class"). Excluded from the Class are defendants herein and any person, firm, trust, corporation, or other entity related to or affiliated with any defendant.
 - 30. This action is properly maintainable as a class action.
- 31. The Class is so numerous that joinder of all members is impracticable. As of September 27, 2017, there were approximately 27,562,795 shares of Alcobra common stock outstanding, held by hundreds, if not thousands, of individuals and entities scattered throughout the country.
- 32. Questions of law and fact are common to the Class, including, among others: (i) whether defendants violated the 1934 Act; and (ii) whether defendants will irreparably harm plaintiff and the other members of the Class if defendants' conduct complained of herein continues.
- 33. Plaintiff is committed to prosecuting this action and has retained competent counsel experienced in litigation of this nature. Plaintiff's claims are typical of the claims of the other members of the Class and plaintiff has the same interests as the other members of the Class. Accordingly, plaintiff is an adequate representative of the Class and will fairly and adequately protect the interests of the Class.
- 34. The prosecution of separate actions by individual members of the Class would create the risk of inconsistent or varying adjudications that would establish incompatible standards of conduct for defendants, or adjudications that would, as a practical matter, be dispositive of the interests of individual members of the Class who are not parties to the adjudications or would substantially impair or impede those non-party Class members' ability to

protect their interests.

35. Defendants have acted, or refused to act, on grounds generally applicable to the Class as a whole, and are causing injury to the entire Class. Therefore, final injunctive relief on behalf of the Class is appropriate.

SUBSTANTIVE ALLEGATIONS

Background of the Company and the Proposed Transaction

- 36. Alcobra is a publicly-traded, emerging pharmaceutical company primarily focused on the development and commercialization of novel treatments for CNS and cognitive disorders such as Attention Deficit Hyperactivity Disorder ("ADHD") and Fragile X syndrome, a rare disease that is the most common single-gene cause of autism and inherited cause of intellectual disability among boys.
- 37. The Company is developing a proprietary Abuse-Deterrent Amphetamine Immediate-Release (ADAIR) for ADHD. ADAIR is an oral formulation of immediate-release (short-acting) dextroamphetamine that is specifically designed to limit abuse by snorting or injecting.
- 38. On September 27, 2017, the Individual Defendants caused the Company to enter into the Merger Agreement.
- 39. Pursuant to the terms of the Merger Agreement, the holders of Arcturus outstanding capital stock immediately prior to the merger will receive ordinary shares of Alcobra. As a result of the Proposed Transaction, Alcobra shareholders are expected to own approximately 40% and Arcturus shareholders are expected to own approximately 60% of the combined company.

- 40. The Proposed Transaction is expected to close during the fourth quarter of 2017, subject to, among other things, the approval by Alcobra's stockholders.
- 41. On September 28, 2017, Alcobra filed two Form 6-Ks with the SEC in connection with the Proposed Transaction.
- 42. The first Form 6-K attached a copy of the Merger Agreement as well as the Press Release announcing the Proposed Transaction.
 - 43. The Press Release stated, in relevant part:

A proxy statement and a proxy card will be filed with the SEC and will be mailed to Alcobra's shareholders seeking any required shareholder approvals in connection with the proposed transactions. Before making any voting or investment decision, investors and shareholders are urged to read the proxy statement (including any amendments or supplements thereto) and any other relevant documents that Alcobra may file with the SEC when they become available because they will contain important information about the proposed transactions.

- 44. Additionally, the Merger Agreement defines "Proxy Statement" as "the proxy statement to be filed with the SEC and addressed to the Alcobra Shareholders in connection with the approval of the Alcobra Shareholder Matters and in connection with the Alcobra Shareholders' Meeting."
- 45. The second Form 6-K attached a Notice of the November 2, 2017 Stockholder Vote on the Proposed Transaction. The Form 6-K provides:

Notice is hereby given that an Extraordinary General Meeting of the Shareholders of Alcobra Ltd. (the "Company") will be held on November 2, 2017, at 10:00 am (Israel Time), at the offices of the Company's counsel (Zysman, Aharoni, Gayer & Co.) at "Beit Zion", 41-45 Rothschild Blvd., 8th Fl., Tel Aviv 6578401, Israel (the "Meeting"), for the sole purpose of approving certain resolutions required in connection with the proposed issuance of a majority interest in the Company's share capital to the owners of Arcturus Inc. in consideration for 100% of the equity securities of Arcturus Inc., which will merge with a wholly-owned subsidiary of the Company and become a wholly-owned subsidiary of the Company (the "Transaction")[]. Such resolutions include: (i) to approve a reverse split of the Company's share capital at a ratio of seven-for-one and to amend the

Company's Amended and Restated Articles of Association (the "Articles") accordingly; (ii) to approve an increase of the Company's share capital by NIS 1,600,000, to NIS 2,100,000, and to amend the Articles accordingly, so that after items (i) and (ii) take effect, Article 2.1.1 of the Articles will be replaced in its entirety with the following: "The registered capital of the Company is NI 2,100,000 divided into 30,000,000 ordinary shares with a par value of NIS 0.07 each."; (iii) to approve a change of the Company's name to "ARCTURUS THERAPEUTICS, LTD."; and (iv) to approve the purchase by the Company of a "run-off" directors' and officers' liability insurance policy for a period of seven years following the effective time of the Transaction.

The resolutions above are to be voted on as one proposal. The Transaction will not be completed if this proposal is not approved.

OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE PROPOSAL ON THE AGENDA

- 46. Neither Form 6-K filed on September 28, 2017 attached a proxy statement or proxy card.
- 47. To date, Alcobra has not filed a proxy statement or proxy card with the SEC in connection with the Proposed Transaction, and plaintiff has not received a proxy statement or proxy card by mail.
- 48. Prior to the Stockholder Vote on the Proposed Transaction, the Company's stockholders must receive a proxy statement that contains, *inter alia*: an accurate description of the process Alcobra's directors used in coming to their decision to support the Proposed Transaction; a fair summary of the Company's value and financial projections as well as the analyses performed by the Company's financial advisor, Ladenburg Thalmann & Co. Inc.; any interests of the Company's officers and directors in the merger; and the Individual Defendants' reasons for recommending the merger.
- 49. Without a proxy statement that contains all material facts regarding the Proposed Transaction, the Company's stockholders cannot make an informed decision with respect to the merger.

50. Accordingly, plaintiff seeks to enjoin the November 2, 2017 Stockholder Vote on the Proposed Transaction.

COUNT I

Claim for Violation of Section 14(a) of the 1934 Act Against the Individual Defendants

- 51. Plaintiff repeats and realleges the preceding allegations as if fully set forth herein.
- 52. Defendants publicly stated that they would file a proxy statement with the SEC, and mail such documents to Alcobra's stockholders, in seeking stockholder approval of the Proposed Transaction.
- 53. The Individual Defendants failed to file a proxy statement with the SEC in connection with the Proposed Transaction, and, based upon information and belief, failed to mail a proxy statement to the Company's stockholders.
- 54. As such, the Individual Defendants have omitted all material facts regarding the Proposed Transaction. By virtue of their positions within the Company, the Individual Defendants were aware of their duty to disclose this information in a proxy statement.
- 55. A reasonable stockholder would consider a proxy statement and the information contained therein important in deciding how to vote on the Proposed Transaction. In addition, a reasonable investor would view a full and accurate disclosure as significantly altering the total mix of information reasonably available to stockholders.
- 56. By reason of the foregoing, defendants violated Section 14(a) of the 1934 Act, and plaintiff and the Class are threatened with irreparable harm, as stockholders cannot make an informed decision with respect to the Proposed Transaction.

PRAYER FOR RELIEF

WHEREFORE, plaintiff prays for judgment and relief as follows:

Case 2:17-cv-04692-JD Document 1 Filed 10/20/17 Page 10 of 11

A. Preliminarily and permanently enjoining defendants and all persons acting in

concert with them from proceeding with, consummating, or closing the Proposed Transaction;

B. In the event defendants consummate the Proposed Transaction, rescinding it and

setting it aside or awarding rescissory damages;

C. Directing the Individual Defendants to disseminate a proxy statement in

connection with the Proposed Transaction, which does not contain any untrue statements of

material fact and that states all material facts required in it or necessary to make the statements

contained therein not misleading;

D. Declaring that defendants violated Section 14(a) of the 1934 Act;

E. Awarding plaintiff the costs of this action, including reasonable allowance for

plaintiff's attorneys' and experts' fees; and

F. Granting such other and further relief as this Court may deem just and proper.

JURY DEMAND

Plaintiff respectfully requests a trial by jury on all issues so triable.

Dated: October 20, 2017

Respectfully submitted,

David M. Promisloff

PROFY PROMISLOFF & CIARLANTO, P.C

David M. Promisloff (ID# 200971)

Joseph M. Profy (ID# 77141)

Jeffrey J. Ciarlanto (ID# 205838)

100 N. 22nd Street, Unit 105

Philadelphia, PA 19103

Tel: (215) 259-5156

Tel. (215) 259 3130

Fax: (215) 600-2642

david@prolawpa.com

profy@prolawpa.com

ciarlanto@prolawpa.com

RIGRODSKY & LONG, P.A.

Brian D. Long (PA Bar No. 82370) Gina M. Serra (PA Bar No. 308207) 2 Righter Parkway, Suite 120 Wilmington, DE 19803 (302) 295-5310

LAW OFFICES OF MARC S. HENZEL

Marc S. Henzel 230 Old Lancaster Road, Suite B Merion Station, PA 19066 (610) 660-8000

Attorneys for Plaintiff

CERTIFICATION OF PLAINTIFF

I, Chuck Shammas ("Plaintiff"), hereby declare as to the claims asserted under the federal securities laws that:

- 1. Plaintiff has reviewed the complaint and authorizes its filing.
- 2. Plaintiff did not purchase the security that is the subject of this action at the direction of Plaintiff's counsel or in order to participate in any private action.
- 3. Plaintiff is willing to serve as a representative party on behalf of the class, either individually or as part of a group, and I will testify at deposition or trial, if necessary. I understand that this is not a claim form and that I do not need to execute this Certification to share in any recovery as a member of the class.
- 4. Plaintiff's purchase and sale transactions in the Alcobra Ltd. (NasdaqGM: ADHD) security that is the subject of this action during the class period is/are as follows:

PURCHASES

SALES

Buy Date	Shares	Price per Share	Sell Date	Shares	Price pe Share
10/1/14	2000	\$14.00			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		 			
			·		

Please list additional transactions on separate sheet of paper, if necessary.

5. Plaintiff has complete authority to bring a suit to recover for investment losses on behalf of purchasers of the subject securities described herein (including Plaintiff, any co-owners, any corporations or other entities, and/or any beneficial owners).

6. During the three years prior to the date of this Certification, Plaintiff has not moved to serve as a representative party for a class in an action filed under the federal securities laws.

7. Plaintiff will not accept any payment for serving as a representative party on behalf of the class beyond Plaintiff's *pro rata* share of any recovery, except such reasonable costs and expenses (including lost wages) directly relating to the representation of the class as ordered or approved by the Court.

I declare under penalty of perjury that the foregoing is true and correct.

Executed this // day of October, 2017.

Chuck Shammas

Case 2:17-cv-04692 TO Page 1 of 2

purpose of initiating the civil d I. (a) PLAINTIFFS	,		DEFENDANTS		
CHUCK SHAMMAS			ALCOBRA LTD, E	I AL.	
(b) County of Residence of First Listed Plaintiff Richmond County, NY (EXCEPT IN U.S. PLAINTIFF CASES)			County of Residence of First Listed Defendant (IN U.S. PLAINTIFF CASES ONLY) NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.		
(c) Attorneys (Firm Name, 1	Address, and Telephone Numbe	r)	Attorneys (If Known)		
Profy Promisloff & Ciarla Philadelphia, PA 19103		St., Unit 105,			
II. BASIS OF JURISDI	ICTION (Place an "X" in O	ne Box Only)	I. CITIZENSHIP OF P (For Diversity Cases Only)	RINCIPAL PARTIES	(Place an "X" in One Box for Plaintig and One Box for Defendant)
☐ 1 U.S. Government Plaintiff	3 Federal Question (U.S. Government)	Not a Party)	P	TF DEF 1	PTF DEF incipal Place
☐ 2 U.S. Government Defendant	☐ 4 Diversity (Indicate Citizenshi)	ip of Parties in Item III)	Citizen of Another State	2	
			Citizen or Subject of a Foreign Country	3 🗖 3 Foreign Nation	□ 6 □ 6
IV. NATURE OF SUIT				D A NYZDY DZICYZ	OTHER STATES
CONTRACT		RTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
□ 110 Insurance □ 120 Marine □ 130 Miller Act □ 140 Negotiable Instrument □ 150 Recovery of Overpayment & Enforcement of Judgment □ 151 Medicare Act □ 152 Recovery of Defaulted Student Loans (Excludes Veterans) □ 153 Recovery of Overpayment of Veteran's Benefits □ 160 Stockholders' Suits □ 190 Other Contract □ 195 Contract Product Liability □ 196 Franchise □ REAL PROPERTY □ 210 Land Condemnation □ 220 Foreclosure □ 230 Rent Lease & Ejectment □ 240 Torts to Land □ 245 Tort Product Liability □ 290 All Other Real Property □ V. ORIGIN (Place an "X" i	□ 330 Federal Employers' Liability □ 340 Marine □ 345 Marine Product Liability □ 350 Motor Vehicle □ 355 Motor Vehicle □ 700 Other Personal Injury □ 362 Personal Injury - Medical Malpractice CIVIL RIGHTS □ 440 Other Civil Rights □ 441 Voting □ 442 Employment □ 443 Housing/ Accommodations □ 445 Amer. w/Disabilities - Employment □ 446 Amer. w/Disabilities - Other □ 448 Education	PERSONAL INJURY 365 Personal Injury - Product Liability 367 Health Care/ Pharmaceutical Personal Injury Product Liability 368 Asbestos Personal Injury Product Liability PERSONAL PROPERTY 370 Other Fraud 371 Truth in Lending 380 Other Personal Property Damage Product Liability PRISONER PETITIONS Habeas Corpus: 463 Alien Detainee 510 Motions to Vacate Sentence 530 General 535 Death Penalty Other: 540 Mandamus & Other 550 Civil Rights 555 Prison Condition 560 Civil Detainee - Conditions of Confinement	□ 625 Drug Related Seizure of Property 21 USC 881 □ 690 Other □ 710 Fair Labor Standards Act □ 720 Labor/Management Relations □ 740 Railway Labor Act □ 751 Family and Medical Leave Act □ 790 Other Labor Litigation □ 791 Employee Retirement Income Security Act □ IMMIGRATION □ 462 Naturalization Application □ 465 Other Immigration Actions	□ 422 Appeal 28 USC 158 □ 423 Withdrawal 28 USC 157 PROPERTY RIGHTS □ 820 Copyrights □ 830 Patent □ 840 Trademark SOCIAL SECURITY □ 861 HIA (1395ff) □ 862 Black Lung (923) □ 863 DIWC/DIWW (405(g)) □ 864 SSID Title XVI □ 865 RSI (405(g)) FEDERAL TAX SUITS □ 870 Taxes (U.S. Plaintiff or Defendant) □ 871 IRS—Third Party 26 USC 7609	□ 375 False Claims Act □ 376 Qui Tam (31 USC 3729(a)) □ 400 State Reapportionment □ 410 Antitrust □ 430 Banks and Banking □ 450 Commerce □ 460 Deportation □ 470 Racketeer Influenced and Corrupt Organizations □ 480 Consumer Credit □ 490 Cable/Sat TV ▼ 850 Securities/Commodities/ Exchange □ 890 Other Statutory Actions □ 891 Agricultural Acts □ 893 Environmental Matters □ 895 Freedom of Information Act □ 896 Arbitration □ 899 Administrative Procedure Act/Review or Appeal of Agency Decision □ 950 Constitutionality of State Statutes
VI. CAUSE OF ACTIO	moved from 3 ate Court Cite the U.S. Civil State Section 14(a) of the Court Brief description of cate Class Action for N	Appellate Court tute under which you are fi he Securities Exchanguse: /iolation of the Federa	(specify ling (Do not cite jurisdictional sta ge Act of 1934	er District Litigation) Transfer tutes unless diversity):	- Litigation - Direct File
VII. REQUESTED IN COMPLAINT:	UNDER RULE 2	IS A CLASS ACTION 3, F.R.Cv.P.	DEMAND \$	CHECK YES only JURY DEMAND:	if demanded in complaint: X Yes No
VIII. RELATED CASI	E(S) (See instructions):	JUDGE		DOCKET NUMBER	
DATE 10/20/2017		SIGNATURE OF ATTOR			
FOR OFFICE USE ONLY RECEIPT # A1	MOUNT	APPLYING IFP	JUDGE	MAG. JUI	DGE

Print Save As... Reset

INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- **I.(a) Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
- (b) County of Residence. For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)
- (c) Attorneys. Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".
- **II. Jurisdiction.** The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.

United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here. United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.

Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.

Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)

- **III. Residence** (citizenship) of Principal Parties. This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- **IV. Nature of Suit.** Place an "X" in the appropriate box. If the nature of suit cannot be determined, be sure the cause of action, in Section VI below, is sufficient to enable the deputy clerk or the statistical clerk(s) in the Administrative Office to determine the nature of suit. If the cause fits more than one nature of suit, select the most definitive.
- **V. Origin.** Place an "X" in one of the seven boxes.

Original Proceedings. (1) Cases which originate in the United States district courts.

Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. When the petition for removal is granted, check this box.

Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.

Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date. Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.

Multidistrict Litigation – Transfer. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407.

Multidistrict Litigation – Direct File. (8) Check this box when a multidistrict case is filed in the same district as the Master MDL docket. **PLEASE NOTE THAT THERE IS NOT AN ORIGIN CODE 7.** Origin Code 7 was used for historical records and is no longer relevant due to changes in statue.

- VI. Cause of Action. Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service
- VII. Requested in Complaint. Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P. Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction. Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- VIII. Related Cases. This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

Date and Attorney Signature. Date and sign the civil cover sheet.

Case 2:17-cv-04692NJDEDSEATHEN PISTRIPLE COV/20/17 Page 1 of 1

FOR THE EASTERN DISTRICT OF PENNSYLVANIA — DESIGNATION FORM to be used by counsel to indicate the category of the case for the purpose of assignment to appropriate calendar.

Address of Plaintiff: 12 Freedom Ave., Staten Isl	and, NY 10314			
Address of Defendant: 101 West Elm Street, Suite 35	0, Conshohocken, PA	19428		
Place of Accident, Incident or Transaction: PA				
	(Use Reverse Side For Additi	•		
Does this civil action involve a nongovernmental corporate party we (Attach two copies of the Disclosure Statement Form in accordance)	· · ·	ny publicly held corporation ownin Yes□		
Does this case involve multidistrict litigation possibilities?		Yes□	No□X	
RELATED CASE, IF ANY: Case Number: Judge		Date Terminated:		
Civil cases are deemed related when yes is answered to any of the fo	ollowing questions:			
Is this case related to property included in an earlier numbered st	uit pending or within one year p	reviously terminated action in this	court?	
		Yes□	No□X	
2. Does this case involve the same issue of fact or grow out of the saction in this court?	ame transaction as a prior suit p	ending or within one year previou	sly terminated	
		Yes□	Notă	
3. Does this case involve the validity or infringement of a patent also	ready in suit or any earlier numb		•	
terminated action in this court?		Yes□	No□X	
4. Is this case a second or successive habeas corpus, social security	appeal, or pro se civil rights car	se filed by the same individual?		
• /		Yes□	_{No} □ X	
CIVIL: (Place / in ONE CATEGORY ONLY)				
A. Federal Question Cases:		B. Diversity Jurisdiction Case	25:	
1. □ Indemnity Contract, Marine Contract, and All C	Other Contracts	1. □ Insurance Contract		
2. □ FELA		2. □ Airplane Personal Injury		
3. □ Jones Act-Personal Injury		3. □ Assault, Defamation		
4. □ Antitrust		4. □ Marine Personal In		
5. □ Patent		5. □ Motor Vehicle Pers	-	
6. □ Labor-Management Relations		6. □ Other Personal Inju	-	
7. □ Civil Rights		7. □ Products Liability	if (Freuse specify)	
8. □ Habeas Corpus		8. □ Products Liability -	— Ashestos	
9. DX Securities Act(s) Cases		9. □ All other Diversity Cases		
10. □ Social Security Review Cases		-		
11. □ All other Federal Question Cases (Please specify)		(Please specify)		
David M. Dramislaff	BITRATION CERTIFION (Check Appropriate Catego			
☐ Pursuant to Local Civil Rule 53.2, Section 3(c)(2), that to the \$150,000.00 exclusive of interest and costs; ☐ Relief other than monetary damages is sought.	el of record do hereby certify: best of my knowledge and belie	f, the damages recoverable in this	civil action case exceed the sum of	
DATE: 10/20/2017 David M. F	Promisloff	200	971	
Attorney-a	at-Law		corney I.D.#	
NOTE: A trial de novo will	be a trial by jury only if there ha	as been compliance with F.R.C.P.	38.	
I certify that, to my knowledge, the within case is not related to except as noted above.	any case now pending or with	in one year previously terminate	ed action in this court	
DATE:10/20/2017 David M. Pro	mialoff	2009	71	
DATE: 10/20/2017 — David M. Proi Attorney-a			rney I.D.#	

CIV. 609 (5/2012)

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

CASE MANAGEMENT TRACK DESIGNATION FORM

CHUCK SHAMMAS	:	CIVIL ACTION		
v.	: :	17 4692		
ALCOBRA LTD., et al.	:	NO.		

In accordance with the Civil Justice Expense and Delay Reduction Plan of this court, counsel for plaintiff shall complete a Case Management Track Designation Form in all civil cases at the time of filing the complaint and serve a copy on all defendants. (See § 1:03 of the plan set forth on the reverse side of this form.) In the event that a defendant does not agree with the plaintiff regarding said designation, that defendant shall, with its first appearance, submit to the clerk of court and serve on the plaintiff and all other parties, a Case Management Track Designation Form specifying the track to which that defendant believes the case should be assigned.

Telephone	one FAX Number E-Mail Address			
215-259-5156	5-259-5156 215-600-2642 david@prolawpa.com			
Date	Attorney-at-law	Attorney for		
10/20/2017	David M. Promisloff	Plaintiff Chuck Shammas	<u>, </u>	
(f) Standard Management -	- Cases that do not fall into any or	ne of the other tracks.	()	
e) Special Management – Cases that do not fall into tracks (a) through (d) that are commonly referred to as complex and that need special or intense management by the court. (See reverse side of this form for a detailed explanation of special management cases.)				
d) Asbestos – Cases involving claims for personal injury or property damage from exposure to asbestos.				
(c) Arbitration – Cases required to be designated for arbitration under Local Civil Rule 53.2.				
b) Social Security – Cases requesting review of a decision of the Secretary of Health and Human Services denying plaintiff Social Security Benefits.				
(a) Habeas Corpus - Cases	brought under 28 U.S.C. § 2241	through § 2255.	()	
SELECT ONE OF THE F	OLLOWING CASE MANAGE	MENT TRACKS:		
	ieves the case should be assigned.		track	

(Civ. 660) 10/02

ClassAction.org

This complaint is part of ClassAction.org's searchable class action lawsuit database and can be found in this post: <u>Stockholder Sues Alcobra</u>, <u>Arcturus Therapeutics Over Missing Proxy Statement</u>